It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Identify Which Dividend Aristocrats ETF Has Highest Expense Ratio and discuss implications for costs and performance.
27,586 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
As bond yields wobble, energy stocks secretly better provide income with inflation protection and strong cash flow. E...
A small BTC sale by Strategy is not a capitulation. The firm says the move funds preferred stock distributions while ...
As markets wobble in mid-2026, retirees rethink growth bets tied to gig-economy platforms. The retirement portfolio c...
A single indicator could steer the next 12 months for the iShares 20+ Year Treasury Bond ETF (TLT). If the 30-year yi...
A high-quality, short-duration AAA CLO ETF is drawing attention by offering more income than 3-month Treasuries. For ...
A biotech ETF posts a 17% gain in the trailing month even as NVIDIA weakens, underscoring a sector rotation that chal...
A fresh analysis shows WisdomTree's WCLD underperforms due to equal-weight rebalancing, turning a $10,000 stake into ...
Solana's SOL token flashed a buy signal, signaling a potential rally. Analysts see targets near $96 and $120 if momen...
As U.S. bond markets stabilize in 2026, investors compare BND and AGG for broad fixed-income exposure. Both funds tra...
In 2026, XLK’s cap-driven approach has quietly outpaced FTEC. Concentration limits are redirecting capital toward sem...
Two oil giants linked to Guyana just posted a staggering combined profit. Here’s what investors need to know about pr...